Impax Laboratories, Inc.
Impax Laboratories, Inc., a prominent player in the pharmaceutical industry, is headquartered in the United States. Founded in 1995, the company has established itself as a leader in the development and manufacturing of generic and specialty pharmaceuticals, focusing on controlled substances and complex formulations. With significant operational regions across North America and Europe, Impax is dedicated to providing high-quality, affordable medications. The company’s core products include a diverse range of generic drugs, as well as proprietary formulations that address unmet medical needs. Impax's commitment to innovation and quality has positioned it favourably in the competitive market, earning recognition for its robust pipeline and strategic partnerships. Notable achievements include successful product launches and a strong presence in the generic pharmaceutical sector, underscoring its role as a trusted provider in the healthcare landscape.
DitchCarbon Score
How does Impax Laboratories, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Impax Laboratories, Inc.'s score of 23 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Impax Laboratories, Inc.'s reported carbon emissions
Impax Laboratories, Inc., headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. Without emissions figures, it is challenging to assess their carbon footprint or climate commitments in detail. However, the absence of documented reduction initiatives or climate pledges suggests that the company may still be in the early stages of formalising its climate strategy. As the pharmaceutical industry increasingly prioritises sustainability, it is essential for companies like Impax to establish clear targets and commitments to reduce their environmental impact.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Impax Laboratories, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
